288391-73-1Relevant articles and documents
Synthesis Routes Towards the Farnesyl Protein Transferase Inhibitor ZARNESTRA
Angibaud, Patrick R.,Venet, Marc G.,Filliers, Walter,Broeckx, Rudy,Ligny, Yannick A.,Muller, Philippe,Poncelet, Virginie S.,End, Dave W.
, p. 479 - 486 (2004)
The discovery that post-translational farnesylation of Ras oncoprotein was an essential step in exercising its biological effect led to the design of farnesyl protein transferase inhibitors (FTIs) in order to control growth of tumors bearing Ras mutations. Pre-clinical studies on murine models have confirmed their inhibitory effect on tumor growth and enabled clinical development. R115777 (ZARNESTRA) is currently undergoing clinical evaluation and recent studies have confirmed its antitumor potential and low toxicity. We wish to describe here the chemical synthesis routes that our group have developed to access ZARNESTRA. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.
Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties
-
, (2008/06/13)
This invention comprises the novel compounds of formula (I) wherein r, s, t, Y1—Y2, R1, R2, R3, R4, R5, R6 and R7 have defined meanings, having farnesyl tra
Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
-
, (2008/06/13)
The present invention relates to compounds of formula 1 and pharmaceutically acceptable salts and solvates thereof wherein R1, R2, R3, R4, R5, R6, R7, R8, R9/sup